StockNews.com Upgrades Actinium Pharmaceuticals (NYSE:ATNM) to Hold

Actinium Pharmaceuticals (NYSE:ATNM) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Stock Up 2.0 %

Shares of Actinium Pharmaceuticals stock traded up $0.03 during midday trading on Wednesday, hitting $1.52. The company’s stock had a trading volume of 352,271 shares, compared to its average volume of 500,097. The firm has a market capitalization of $47.42 million, a P/E ratio of -1.09 and a beta of 0.10. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $10.24. The stock has a 50-day simple moving average of $1.27 and a 200-day simple moving average of $1.44.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Large investors have recently made changes to their positions in the company. Vontobel Holding Ltd. acquired a new stake in Actinium Pharmaceuticals in the fourth quarter valued at approximately $32,000. Sei Investments Co. acquired a new stake in shares of Actinium Pharmaceuticals in the 4th quarter valued at $62,000. Barclays PLC lifted its stake in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares during the last quarter. Bank of America Corp DE boosted its holdings in Actinium Pharmaceuticals by 76.6% in the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Actinium Pharmaceuticals during the third quarter worth $112,000. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).